Retatrutide phase 3 results explained: the 2026 TRIUMPH topline

TRIUMPH is Lilly's phase 3 program for retatrutide, a once-weekly peptide that activates the GLP-1, GIP and glucagon receptors. The trials randomized adults with obesity or overweight to retatrutide or placebo, escalated the dose every 4 weeks from a 1 or 2 mg start toward maintenance arms of 4, 8 or 12 mg, and measured percent change in body weight from baseline as the primary endpoint. TRIUMPH-1 ran 80 weeks; TRIUMPH-2 and TRIUMPH-3 covered other populations in the program, and Lilly reported that both met their primary endpoints.

The phase 2 trial published in 2023 is still the only peer-reviewed efficacy source. It reported about 24 percent average loss at 48 weeks on 12 mg with the curve still falling, which made a larger number at 80 weeks the expected result. The phase 3 topline confirmed the direction and extended the duration.

About 28 percent at 80 weeks is a trial average at the top dose. Averages hide a wide spread: in every GLP-1 trial to date, some participants lost very little and others lost far more than the mean, and there is no reason to expect retatrutide to be different. Roughly 70 lb is the pound equivalent for the average participant in a trial whose average starting weight was in the range typical of these studies, not a prediction for any individual.

It is also the number for people who stayed on the drug for 80 weeks under trial conditions, with free medication, scheduled visits and lifestyle counselling. Lilly's topline wording will state whether the figure uses the efficacy estimand (what happens if everyone takes the drug as directed) or the treatment-regimen estimand (what happened to everyone randomized, including those who stopped); the two usually differ by a few percentage points. Until the paper is out, that detail is unknown, and it matters when comparing to other trials.

The number came from a press release. Topline means the database has been locked and the headline result computed, but the data have not been peer reviewed, the full adverse event tables have not been published, and the secondary endpoints have not been scrutinized. Press release figures from Lilly and Novo Nordisk have generally held up on publication, which is reassuring without being the same as a published trial.

Tirzepatide's SURMOUNT-1 reported about 20.9 percent average loss at 15 mg over 72 weeks. Semaglutide's STEP 1 reported about 15 percent at 2.4 mg over 68 weeks. Retatrutide's TRIUMPH-1 topline reports about 28 percent at 12 mg over 80 weeks. On the surface that is a clean ladder: 15, 21, 28. The compound page describes retatrutide as larger on paper and unproven in practice, and that remains the right framing.

The ladder is not a head-to-head comparison. The three trials enrolled different populations, ran for different lengths, used different estimands and were conducted years apart as the baseline standard of care shifted. The only head-to-head trial in this group is SURMOUNT-5, where tirzepatide beat semaglutide directly at about 20 versus 14 percent. No trial has compared retatrutide to either drug, and until one does, the ranking is suggestive rather than established.

What the cross-trial pattern does support is the biological argument: adding GIP to GLP-1 produced more loss than GLP-1 alone, and adding glucagon on top appears to produce more still. The glucagon component raises energy expenditure and drives liver fat oxidation, which is a different lever from appetite suppression. The three-way comparison and the retatrutide vs tirzepatide page go through the trade-offs.

Lilly has said it plans to submit retatrutide to the FDA in the first quarter of 2027. A standard review takes about ten months from acceptance, and a priority review about six, so even on the fastest track an approval decision is not expected before late 2027. Launch, pricing, insurance coverage and supply ramp follow approval, not precede it, which pushes real-world access further out again.

The timeline has a direct effect on the grey market. Until a pharmaceutical product exists, every vial labeled retatrutide is unregulated powder of unverified purity, and the compound page is explicit that identity and concentration vary between suppliers. Demand driven by the 28 percent headline lands on a supply chain that nobody is checking. Approval will not make grey-market vials legitimate, but it will create a tested product to compare them against.

Approval also brings a label. Right now the only dosing information is what the trials did, and the trials were designed to test fixed arms, not to tell a person how to escalate or when to hold. A label will carry missed-dose rules, restart guidance, contraindications and the full adverse event profile. The retatrutide dosage chart is built on the trial schedule and will be updated when a label exists.

A topline announcement answers one question: did the trial hit its primary endpoint, and by how much. It is written by the sponsor, reviewed by the sponsor's lawyers for securities purposes, and released to investors before clinicians. It typically includes the primary endpoint, a handful of key secondaries and a one-paragraph summary of safety, usually saying the profile was consistent with earlier trials.

What it leaves out is everything that lets a reader judge the result: the full adverse event tables, discontinuation rates by arm and reason, the confidence intervals, the subgroup analyses, the estimand definitions and the handling of missing data. For a drug class where GI side effects drive dropouts and where retatrutide specifically carries a heart rate signal, the discontinuation data are as important as the efficacy data, and they are not yet available in detail.

Cardiovascular outcomes are the biggest gap. Semaglutide has the SELECT trial, which showed a 20 percent reduction in major cardiovascular events in people with obesity and heart disease. Tirzepatide has SURPASS-CVOT, which showed cardiovascular outcomes at least as good as dulaglutide in type 2 diabetes. Retatrutide has no outcomes trial reported, and the glucagon-driven heart rate increase is exactly the kind of signal an outcomes trial exists to resolve. Whether a sustained rise of several beats per minute matters over years is unknown.

Long-term safety is the second gap. Eighty weeks is a long trial but a short treatment, and the compound page's cycle note assumes weight regain after stopping, as with every other GLP-1 class drug, because there is no withdrawal study yet. The skin tingling (dysesthesia) seen in a minority of phase 2 participants, the thyroid, pancreatitis and gallbladder warnings assumed by class, and the effect on lean mass all need the full data.

The third gap is comparative. Without a trial against tirzepatide, nobody can say how much of the extra loss is the drug and how much is the trial. The GLP-1 side effects article covers the class warnings, including the January 2026 MHRA alert on pancreatitis, and muscle loss on GLP-1 drugs covers the body composition question that a larger weight loss makes more pressing.

The results confirm the pharmacology works and do nothing to change the status of the product people can buy. Retatrutide is unapproved, on the WADA prohibited list, and sold only as research-grade powder. The trial numbers come from pharmaceutical-grade material at verified doses under medical supervision, none of which applies to a vial from a vendor. Third-party testing, covered in how to read a COA, is the only check available.

For people weighing options, the honest summary is that tirzepatide is approved, labeled, tested and produces about 21 percent in its trial; retatrutide may produce more and has none of those things. Our weight loss compound guide and are peptides safe cover the broader decision. This page will be updated when the TRIUMPH papers are published and again when a regulatory decision is announced.